Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. NTLA
NTLA logo

NTLA News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NTLA News

Investment Choices in Gene Editing and Rare Disease Treatments

23h agoNASDAQ.COM

Choosing Between Gene Editing and Orphan Disease Treatments

1d agoFool

Biotech Sector Sees FDA Approvals and Layoffs

2d agoNASDAQ.COM

Intellia Therapeutics Shows Significant Progress, Stock Up 58%

4d agoFool

Intellia Therapeutics' Drug Phase 3 Trial Success

4d agoNASDAQ.COM

Intellia Therapeutics Shows Significant Progress, Stock Up 58%

4d agoYahoo Finance

Regentis Soars After Withdrawing US Listing Application

5d agoNASDAQ.COM

Intellia's Treatment Candidate Shows Promising Results

5d agoYahoo Finance

NTLA Events

06/17 12:30
Intellia Therapeutics Stock Rises 12.9% to $16.43
Intellia Therapeutics is up 12.9%, or $1.88 to $16.43.
06/17 10:30
Intellia Therapeutics Stock Rises 10.7% to $16.11
Intellia Therapeutics is up 10.7%, or $1.56 to $16.11.
06/15 16:30
Major U.S. Indices Surge on U.S.-Iran Peace Agreement
The major averages finished sharply higher following a preliminary U.S.-Iran peace agreement that could reopen the Strait of Hormuz and significantly ease pressure on global energy markets. Brent crude oil prices have dropped to roughly three-month lows after the announced agreement, easing concerns about supply disruptions and helping reduce inflation fears that had weighed on stocks throughout the spring.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Fox Corp.Rokufor $160 per shareSalesforcecustomer agent company Fin for $3.6BNuveiPayoneer Globalfor $7.40 per share in cash, or $2.75BTripAdvisorto American Expressfor $700M in cashThe U.K. government isfor children under the age of 162. WALL STREET CALLS:TruistDatadogto Buy, sees opportunity for continued upsideOld Dominionto Sell at CitiKeyBancFireFly Aerospaceand Rocket Labto Overweight after their SpaceX related selloffsAccentureto Equal Weight at Morgan StanleyFerrarito Overweight at Morgan Stanley3. AROUND THE WEB:Centeneis offering voluntary buyouts to most employees, Bloomberg reportsTeslarecently presented self-published safety statistics to regulators in Sweden and Netherlands, but independent traffic-safety researchers argue the statistics are misleading marketing, Reuters saysMatt Holt's investment firm Thoreau Group, which is backed by Apollo Global, is in advanced discussions to acquire Ensemble Health Partners in a deal that would value the company at roughly $12B, Bloomberg saysSBA Communications'potential take-private process involving KKRand Brookfieldhas stalled and is now considered effectively dead, as negotiations have come to a standstill in recent weeks, sources tell GreenstreetAccording to an Indian pollution regulator, wastewater from a Tata components factory for Apple'siPhone has allegedly contaminated groundwater, impacting nearby farms, Reuters says4. MOVERS:Oustergained afterwith Benchmark ElectronicsIntellia Therapeuticsincreased after presenting resultsStriveclosed higher afterand reporting holdings of 19,105 as of June 12Pattern Groupfinished lower afterAlcoafell after announcing the ratification of a5. EARNINGS/GUIDANCE:PowerFleet, with EPS and revenue beating consensusCoda Octopus, with EPS higher year-over-yearFiservbacked itsenGene, with EPS beating consensusJerash Holdingsand provided guidance for Q1INDEXES:The Dow rose 468.77, or 0.92%, to 51,671.03, the Nasdaq gained 795.10, or 3.07%, to 26,683.94, and the S&P 500 advanced 122.83, or 1.65%, to 7,554.29.
06/15 13:00
Major Averages Surge on U.S.-Iran Peace Agreement
The major averages were sharply higher near noon as investors return from the weekend focused on a preliminary U.S.-Iran peace agreement that could reopen the Strait of Hormuz and significantly ease pressure on global energy markets. Brent crude oil prices have dropped to roughly three-month lows after the announced agreement, easing concerns about supply disruptions and helping reduce inflation fears that had weighed on stocks throughout the spring.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Fox Corp.Rokufor $160 per shareSalesforcecustomer agent company Fin for $3.6BNuveiPayoneer Globalfor $7.40 per share in cash, or $2.75BTripAdvisorwillto American Expressfor $700M in cashThe U.K. government isfor children under the age of 162. WALL STREET CALLS:TruistDatadogto Buy, sees opportunity for continued upsideOld Dominionto Sell at CitiKeyBancFireFly Aerospaceand Rocket Labto Overweight after their SpaceX related selloffsAccentureto Equal Weight at Morgan StanleyFerrarito Overweight at Morgan Stanley3. AROUND THE WEB:CommerzbankCEO Bettina Orlopp said the bank was surprised by allegations from UniCreditthat it had misled the public, highlighting rising tensions between the two banks, Reuters saysTeslarecently presented self-published safety statistics to regulators in Sweden and Netherlands, but independent traffic-safety researchers argue the statistics are misleading marketing, Reuters saysMatt Holt's investment firm Thoreau Group, which is backed by Apollo Global, is in advanced discussions to acquire Ensemble Health Partners in a deal that would value the company at roughly $12B, Bloomberg saysSBA Communications'potential take-private process involving KKRand Brookfieldhas stalled and is now considered effectively dead, as negotiations have come to a standstill in recent weeks, sources tell GreenstreetAccording to an Indian pollution regulator, wastewater from a Tata components factory for Apple'siPhone has allegedly contaminated groundwater, impacting nearby farms, Reuters says4. MOVERS:Oustergains afterwith Benchmark ElectronicsIntellia Therapeuticsincreases afterfrom its Phase 3 HAELO trialStrivehigher afterand reporting holdings of 19,105 as of June 12Pattern Grouplower after filing toAlcoafalls after announcing the ratification of awith USW5. EARNINGS/GUIDANCE:PowerFleet, with EPS and revenue beating consensusCoda Octopus, with EPS higher year-over-yearFiservfor FY26enGene, with EPS beating consensusJerash Holdingsand provided guidance for Q1INDEXES:Near midday, the Dow was up 1.37%, or 703.88, to 51,906.14, the Nasdaq was up 2.99%, or 773.00, to 26,661.85, and the S&P 500 was up 1.91%, or 141.58, to 7,573.04.

NTLA Monitor News

Intellia Reports Positive Phase 3 Trial Results for Lonvo-z

Jun 17 2026

Intellia Reports Positive Phase 3 Results for Lonvo-z

Jun 15 2026

Intellia to Present HAELO Trial Data at EAACI Congress

Jun 05 2026

Intellia to Present HAELO Trial Data, Boosting Lonvo-z's Market Potential

Jun 04 2026

Intellia Therapeutics stock rises amid sector rotation

May 27 2026

Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027

May 14 2026

Intellia Reports Positive Phase 3 Data for Lonvo-z, Plans U.S. Launch in 2027

May 11 2026

Intellia Initiates BLA Submission for Lonvo-z in HAE Treatment

Apr 30 2026

NTLA Earnings Analysis

No Data

No Data

People Also Watch